Physician profile
Taylor E Lemke
NPI 1740743103
$9,061.88
in general payments reported to CMS, 2019-2025
21 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,259 · 2022: $1,620 · 2023: $2,647 · 2024: $1,237 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,157.79 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,789.13 | 2021-2025 | Proclaim, Eterna, Prodigy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,665.33 | 2021-2024 | Relistor |
| Boston Scientific Corporation | $752.84 | 2021-2025 | Infinion 16, General - Therapies, Infinion 16 |
| Forte Bio-Pharma LLC | $339.89 | 2022-2023 | Prolate, Nalocet |
| Collegium Pharmaceutical, INC. | $283.84 | 2021-2024 | Belbuca, Xtampza |
| Arbor Pharmaceuticals, INC. | $198.54 | 2021-2022 | |
| Nevro Corp. | $176.27 | 2021-2023 | Senza |
| Scilex Pharmaceuticals INC. | $127.28 | 2021-2023 | Ztlido |
| Azurity Pharmaceuticals, INC. | $115.50 | 2023 | Horizant |
| Teva Pharmaceuticals USA, INC. | $100.15 | 2021 | |
| Medtronic, INC. | $81.39 | 2022 | |
| Amgen INC. | $77.03 | 2021-2022 | |
| Abbvie INC. | $70.58 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.92 | 2022 | |
| Akebia Therapeutics INC | $46.67 | 2024 | Vafseo, Auryxia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $46.05 | 2021 | |
| Redhill Biopharma INC. | $38.89 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $37.54 | 2021 | |
| Baxter Healthcare | $18.95 | 2024 | Renal - Acute |
| Idorsia Pharmaceuticals US INC | $15.76 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.33 | 2024 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Lemke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.